Corcept Therapeutics (CORT) Stock Forecast & Price Target

Corcept Therapeutics is supported by a stronger commercial base as Korlym’s transition to Curant Rare in February appears to have removed the supply-chain bottleneck, with March and April marking all-time highs in paid patient starts and management expecting sales growth over the next two quarters as patients titrate to target dose. The bull case is further reinforced by a de-risked relacorilant pathway after the December 2025 Complete Response Letter, since the FDA acknowledged the pivotal GRACE trial met its primary endpoint and GRADIENT provided confirmatory evidence, while management believes the additional efficacy-focused analysis should support a Class II resubmission on a 6-month review clock and potentially a PDUFA date as early as 4Q26. Longer term, the company has multiple value drivers beyond Cushing’s syndrome, including Lifyorli’s U.S. launch on April 1, 2026, the international opportunity suggested by $50M of non-U.S. sales out of $211M global sales in 2Q26, and a pipeline spanning oncology, ALS, and MASH, which helps justify an average enterprise value of approximately $12.5B to $21.6B across the cited valuation frameworks.

Corcept Therapeutics is facing a negative outlook because, despite near-term regulatory milestones such as the expected final EC decision by November 23, 2026 and management’s estimate of 4Q26, the investment case still depends heavily on execution rather than de-risked economics, with the cited EU precedent only offering a limited proxy for approval timing. The enthusiasm around Lifyorli’s rapid early adoption in PROC is encouraging but still narrow, as more than 200 unique prescribers represented only about 4% of the ~5,000 targeted physicians, meaning the commercial ramp remains in its infancy and is not yet broad enough to offset the company’s dependence on a single franchise. Even with modeled sales beginning in 2Q26 at $23M and rising to $167M in FY2026, the path to $1.6B by 2034 appears long and uncertain, while the rest of the pipeline in solid tumors, ALS, and MASH remains clinical-stage and therefore carries substantial development and valuation risk.